Mylan II B.V.

Delisted

CIK 1623613fmd_0PP5HP0HGG0BGWYZR0QNM8MD6GManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2012 to Sep 30, 2020, 32 periods

Income Statement · Annual · Millions · USD
Line item	FY2012	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019
Total revenues	6,796	6,909	7,720	9,429	11,077	11,908	11,434	11,501
Cost of revenue	3,888	3,869	4,192	5,213	6,380	7,125	7,432	7,603
Gross profit	2,908	3,040	3,528	4,216	4,697	4,783	4,002	3,898
Research and development	401	508	582	672	827	783	705	640
Selling, general and administrative	1,392	1,409	1,626	2,181	2,499	2,576	2,441	2,564
Total operating expenses	1,799	1,905	2,175	2,755	3,998	3,346	3,096	3,182
Operating income	1,109	1,136	1,353	1,461	699	1,437	906	716
Interest expense	309	313	333	339	455	535	542	517
Other non-operating income (expense)	4	(75)	(45)	(206)	(123)	0	(65)	(44)
Income before taxes	804	747	975	915	122	903	298	154
Income tax expense	161	121	41	68	(358)	207	(54)	138
Net income from continuing operations	643	627	933	848	480	696	353	17
Net income	643	627	933	848	480	696	353	17
Net income to common shareholders	641	624	929	848	480	–	–	–